Whole-genome sequencing and phylogenetic analysis of isolated from pullets through final raw product in the processing plant of a conventional broiler complex: a longitudinal study.

Unlabelled: are Gram-negative, rod-shaped, entero-invasive foodborne bacteria and are frequently detected in chicken houses and facilities of poultry broiler complexes. The objective of this study was to determine the prevalence, critical entry points, and movement pattern of along different stages of a complex. A total of 1,071 environmental samples were collected from 38 production houses (8 pullet, 10 breeder, and 20 broiler), a hatchery, 6 transport trucks, and a processing plant.

Cell-specific delivery of GJB2 restores auditory function in mouse models of DFNB1 deafness and mediates appropriate expression in NHP cochlea.

Mutations in the gene cause the most common form of human hereditary hearing loss, known as DFNB1. is expressed in two cell groups of the cochlea-epithelial cells of the organ of Corti and fibrocytes of the inner sulcus and lateral wall-but not by sensory hair cells or neurons. Attempts to treat mouse models of DFNB1 with AAV vectors mediating nonspecific expression have not substantially restored function, perhaps because inappropriate expression in hair cells and neurons could compromise their electrical activity.

Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review.

Purpose: Metabolic disease, including obesity and type 2 diabetes, are amongst the most significant health issues facing women of reproductive age. To date, no antenatal weight management tools have reduced the risk of adverse health outcomes for women with obesity and their offspring, resulting in a shift in focus to the pre-conception period. Although not yet recognised in most international weight management guidelines, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are being increasingly used for weight management prior to conception.

Surgical parathyroidectomy in pregnancy for severe secondary hyperparathyroidism associated with end-stage kidney disease.

Secondary hyperparathyroidism (SHPT) is common in patients with end-stage kidney disease (ESKD) on kidney replacement therapy, which leads to abnormalities of bone and mineral metabolism. Patients conceiving on kidney replacement therapy add a further layer of complexity to the management of their SHPT. Existing literature in cases of primary hyperparathyroidism (PHPT) has linked untreated hyperparathyroidism to increased maternal and fetal morbidity, including hypertensive disorders of pregnancy, fetal growth restriction and neonatal hypocalcaemia.